The pace of weight return depends partly on how long you took the medication
NICE has published guidance on pharmacological interventions for weight management, including NICE guideline CG189 (Obesity: identification, assessment and management) and a technology appraisal supporting the use of semaglutide (Wegovy) for adults with a BMI of 35 kg/m or above (or 3034.9 kg/m in certain circumstances) alongside a specialist weight management service
This is NOT suitable for those with sensitive skin
This is fascinating and it brings it back to this question that we had before, and I appreciate that you've answered it very clearly
This page lists the no-DAC form of CJC-1295, which is short-acting - not the long-acting 'with DAC' form
Tong G, Peng T, Chen Y, Sha L, Dai H, Xiang Y, et al